HEALTH PROFESSIONAL · SOURCE READING

ATA pediatric intermediate risk

Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Differentiated Thyroid Cancer (Papillary/Follicular) / Treatment of Papillary and Follicular Thyroid Carcinoma / Postoperative staging and long-term surveillance

Initial postoperative staging includes a TSH-stimulated thyroglobulin and diagnostic 123I whole-body scan for further stratification and determination with 131I.

TSH suppression should be targeted to serum levels of 0.1 to 0.5 mIU/L.

In patients with no evidence of disease, surveillance should include ultrasonography at 6 months postoperatively and then every 6 to 12 months for 5 years (and then less frequently), as well as thyroglobulin levels (on hormone replacement therapy) every 3 to 6 months for 3 years and then annually.

TSH-stimulated thyroglobulin and diagnostic 123I scan should be considered in 1 to 2 years for patients treated with 131I.

Preserved source evidence · Not medical advice